The verdict
Our read at a glance.
Whether a SERM can shrink breast tissue that has already formed, as opposed to preventing it forming.
- The signal
- Its approved evidence base is in postmenopausal osteoporosis and breast cancer risk reduction, with large trial programmes and labelled products. The use here rests on a much smaller literature: comparative work in adolescent gynaecomastia reported greater reduction in breast diameter with raloxifene than with tamoxifen, and it has been examined in pubertal gynaecomastia specifically. That is a real signal in a small population, and it is the basis for a use in adult men that has never been trialled directly.
- The unknown
- Whether the paediatric findings transfer to adult men with androgen-induced gynaecomastia, which differs in cause, duration and tissue composition from pubertal gynaecomastia.
- Our read
- A rare case where the off-label use has a real, if narrow, evidence base - and a boxed warning for stroke and clots that is being accepted for a cosmetic indication. That trade should be made deliberately rather than by default.
The mechanism
How it works.
Raloxifene is a selective oestrogen receptor modulator: an antagonist at the oestrogen receptor in breast tissue and an agonist in bone, which is why it both reduces breast cancer risk and preserves bone density. In gynaecomastia, the glandular tissue proliferates under oestrogen signalling, usually because the ratio of oestrogen to androgen has shifted - which is what happens when aromatising androgens are taken in quantity. Blocking the receptor in that tissue removes the growth signal. The reason it may act on established tissue where other agents do not is thought to relate to the strength and duration of receptor blockade in glandular tissue, though the comparison rests on a small trial rather than a mechanistic demonstration. Unlike tamoxifen, it does not have agonist activity in the endometrium, which changes its side-effect profile but not its thrombotic risk.
Safety & regulatory boundary
The consequential part.
Approved for osteoporosis and breast cancer risk reduction in postmenopausal women; use in men is off-label. It carries a boxed warning for venous thromboembolism and death from stroke, and that risk does not disappear because the patient is male. Because it is oestrogen-antagonistic in some tissues and agonistic in others, its effect on bone in men is not the same as its studied effect in postmenopausal women.
What's next
What we're watching.
Any trial in adult male gynaecomastia, which would be the first direct evidence for the way it is used here.
Context
Why this is discussed.
Once gynaecomastia is established, tamoxifen and aromatase inhibitors do very little, and surgery is the usual answer - so anything with evidence for reversal matters.
The evidence base
23 cited references.
Regulatory & labels3
NorthStar Rx LLC (FDA label) · 2024
A-S Medication Solutions (FDA label) · 2023
Exelan Pharmaceuticals, Inc. (FDA label) · 2020
Registered trials8
ClinicalTrials.gov · COMPLETED · 2021-07-15
ClinicalTrials.gov · PHASE2/PHASE3 · ACTIVE_NOT_RECRUITING · 2025-06-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-12-03
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-03
ClinicalTrials.gov · PHASE1 · RECRUITING · 2026-01
ClinicalTrials.gov · NA · COMPLETED · 2014-02
ClinicalTrials.gov · NA · RECRUITING · 2024-03-08
ClinicalTrials.gov · NA · COMPLETED · 2017-02-15
Indexed literature (PubMed)12
Seidler ZE et al. · Clin Psychol Rev · 2016
Addis ME et al. · Am Psychol · 2003
René C et al. · Rech Soins Infirm · 2025
Griffith DM · Am J Mens Health · 2020
Oliffe JL et al. · Am J Mens Health · 2015
Nordt CA et al. · Curr Opin Pediatr · 2008
Gomes R et al. · Salud Colect · 2020
Rodriguez R · AIDS Wkly Plus · 1999
Scott-Storey K et al. · Trauma Violence Abuse · 2023
MacLean S et al. · Int J Drug Policy · 2020
Vickery A · Health Soc Care Community · 2022
Yu Ko WF et al. · Am J Mens Health · 2020
Keep reading